Literature DB >> 16679264

Reduced rate of alveolar-capillary recruitment and fall of pulmonary diffusing capacity during exercise in patients with heart failure.

Lyle J Olson1, Eric M Snyder, Kenneth C Beck, Bruce D Johnson.   

Abstract

BACKGROUND: Patients with chronic heart failure (CHF) have reduced pulmonary diffusing capacity for carbon monoxide (DLCO). Acute pulmonary congestion also causes reduction of DLCO, which is reversible. We hypothesized for patients with CHF that the rate of rise of exercise DLCO is reduced compared to healthy controls and falls near end-exercise consistent with progressive interstitial edema. METHODS AND
RESULTS: DLCO and pulmonary blood flow (QC)) were measured by a rebreathe technique in CHF subjects (n = 11) and controls (n = 8) at rest, during constant workload exercise, and after exercise. DLCO of CHF subjects was less than controls at rest (16.5 +/- 1 vs. 21.9 +/- 2 mL/min/mm Hg, P < .01). CHF subjects exercised 11 +/- 2 minutes to 90% peak VO2, whereas controls exercised 17 +/- 2 minutes, reaching 88% peak VO2. In CHF subjects, DLCO increased to 19 +/- 2 mL/min/mm Hg and for controls to 38 +/- 3 mL/min/mm Hg. During the final 3 minutes of exercise, DLCO increased 5% in controls while decreasing 5% in CHF subjects (DLCO/Q(C)) was lower in CHF subjects at rest and progressively lower throughout exercise (P < .01).
CONCLUSION: In patients with CHF, DLCO has reduced rate of rise with exercise and falls near end-exercise consistent with limitation of alveolar-capillary recruitment and progressive interstitial edema.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679264     DOI: 10.1016/j.cardfail.2006.01.010

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  8 in total

1.  Influence of lung volume, fluid and capillary recruitment during positional changes and exercise on thoracic impedance in heart failure.

Authors:  Chul-Ho Kim; Matthew A Fuglestad; Maile L Ceridon Richert; Win K Shen; Bruce D Johnson
Journal:  Respir Physiol Neurobiol       Date:  2014-08-14       Impact factor: 1.931

2.  Influence of Inhaled Amiloride on Lung Fluid Clearance in Response to Normobaric Hypoxia in Healthy Individuals.

Authors:  Courtney M Wheatley; Sarah E Baker; Bryan J Taylor; Manda L Keller-Ross; Steven C Chase; Alex R Carlson; Robert J Wentz; Eric M Snyder; Bruce D Johnson
Journal:  High Alt Med Biol       Date:  2017-09-06       Impact factor: 1.981

Review 3.  Clinical Classification of Heart Failure Patients Using Cardiac Function during Exercise.

Authors:  Eric M Snyder; Erik H Van Iterson; Thomas P Olson
Journal:  Exerc Sport Sci Rev       Date:  2015-10       Impact factor: 6.230

4.  Left atrial size, chemosensitivity, and central sleep apnea in heart failure.

Authors:  Andrew D Calvin; Virend K Somers; Bruce D Johnson; Christopher G Scott; Lyle J Olson
Journal:  Chest       Date:  2014-07       Impact factor: 9.410

5.  Impaired Pulmonary Diffusion in Heart Failure With Preserved Ejection Fraction.

Authors:  Thomas P Olson; Bruce D Johnson; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2016-06       Impact factor: 12.035

6.  Rapid intravenous infusion of 20 ml/kg saline does not impair resting pulmonary gas exchange in the healthy human lung.

Authors:  G Kim Prisk; I Mark Olfert; Tatsuya J Arai; Peter D Wagner; Susan R Hopkins
Journal:  J Appl Physiol (1985)       Date:  2009-11-12

7.  Pulmonary and right ventricular dysfunction are frequently present in heart failure irrespective of left ventricular ejection fraction.

Authors:  Wouter Robaeys; Sema Bektas; Josiane Boyne; Vanessa van Empel; Nicole Uszko-Lencer; Christian Knackstedt; Hans-Peter Brunner-La Rocca
Journal:  Heart Asia       Date:  2017-08-16

Review 8.  Exercise Intolerance in Heart Failure: Central Role for the Pulmonary System.

Authors:  Sophie Lalande; Troy J Cross; Manda L Keller-Ross; Norman R Morris; Bruce D Johnson; Bryan J Taylor
Journal:  Exerc Sport Sci Rev       Date:  2020-01       Impact factor: 6.642

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.